Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14937203 | 0.91 | L3MBTL1 (0.72) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL4719310 | 0.89 | L3MBTL1 (0.61) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL10489948 | 0.89 | L3MBTL1 (0.61) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL10458609 | 0.89 | LMNA (0.73) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL29242263 | 0.89 | LMNA (0.73) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL10458600 | 0.89 | LMNA (0.73) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL29067692 | 0.89 | LMNA (0.73) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL25009812 | 0.85 | L3MBTL1 (0.76) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL30556174 | 0.85 | L3MBTL1 (0.76) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL4203340 | 0.84 | L3MBTL1 (0.61) | L3MBTL1LMNAALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2885307-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2015-06-24 | — | — | EP | claimed |
| CN-104428305-A | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators | ACTELION PHARMACEUTICALS LTD | 2015-03-18 | — | — | CN | claimed |
| WO-2014006585-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-09 | — | — | WO | claimed |
| EP-1633334-B1 | TOPICAL ADMINISTRATION OF VASOACTIVE VITAMIN B3 COMPOUNDS FOR PROMOTING SLEEP | PROCTER & GAMBLE (US) | 2006-11-15 | — | — | EP | claimed |
| EP-1633334-A2 | A METHOD OF PROMOTING SLEEP USING TOPICAL ADMINISTRATION OF VASOACTIVE AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2005002554-A2 | A METHOD OF PROMOTING SLEEP USING TOPICAL ADMINISTRATION OF VASOACTIVE AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2005-01-13 | — | — | WO | claimed |
| US-20040254202-A1 | Method of promoting sleep using topical administration of vasoactive agents | THE PROCTER & GAMBLE COMPANY | 2004-12-16 | — | — | US | claimed |
| EP-3322419-B1 | SYNTHESES, ACTIVITIES, AND METHODS OF USE OF DIHYDRONICOTINAMIDE RIBOSIDE DERIVATIVES | UNIV CORNELL (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20240392273-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| EP-3624846-B1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY INCLUDING A COMBINATION OF NICOTINIC ACID AND TRYOPTOPHAN | BHAMIS RES LABORATORY PVT LTD (IN) | 2024-08-07 | — | — | EP | disclosed |
| EP-4401758-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | Takeda Pharmaceutical Company Limited (JP) | 2024-07-24 | — | — | EP | disclosed |
| CN-118139636-A | Delivery of promoted concentrated antibody formulations using hyaluronidase | 武田药品工业株式会社 | 2024-06-04 | — | — | CN | disclosed |
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-11 | — | — | US | disclosed |
| EP-2599769-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID AMIDE | Sumitomo Chemical Company Limited (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20130123505-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID AMIDE | SUMITOMO CHEMICAL COMPANY, LIMITED | 2013-05-16 | — | — | US | disclosed |
| US-20090318510-A1 | TOPICAL DRUG DELIVERY SYSTEM | GLYCOBIOSCIENCES, INC. (CA) | 2009-12-24 | — | — | US | disclosed |
| EP-1633334-B1 | TOPICAL ADMINISTRATION OF VASOACTIVE VITAMIN B3 COMPOUNDS FOR PROMOTING SLEEP | PROCTER & GAMBLE (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1633334-A2 | A METHOD OF PROMOTING SLEEP USING TOPICAL ADMINISTRATION OF VASOACTIVE AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005002554-A2 | A METHOD OF PROMOTING SLEEP USING TOPICAL ADMINISTRATION OF VASOACTIVE AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20040254202-A1 | Method of promoting sleep using topical administration of vasoactive agents | THE PROCTER & GAMBLE COMPANY | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | ALB, TTR, MAX | L3MBTL1 2534/4885LMNA 2955/4885ALDH1A1 4823/4885 |
| US-20130123505-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID AMIDE | HCAR2, NAAA, FAAH2 | L3MBTL1 4136/4885LMNA 3379/4885ALDH1A1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.